Combination approaches—such as ferroptosis inducers with immune checkpoint inhibitors—may restore anti-tumor immunity, reprogram suppressive myeloid cells, and overcome resistance to PD-1/PD-L1 blockade. Here, CD274 is linked to neoplasm.